Essential Reads: Are Premenstrual Mood Symptoms a Risk Factor for Suicide?
Women with premenstrual mood disorders face significantly higher risk of suicidal ideation and behavior, highlighting the need for careful assessment and targeted prevention.
Women with premenstrual mood disorders face significantly higher risk of suicidal ideation and behavior, highlighting the need for careful assessment and targeted prevention.
This preliminary study demonstrates the potential benefits of increasing the dosage of psychostimulant medication premenstrually in women with ADHD who experience premenstrual worsening of ADHD and mood symptoms.
A new study from Miller and colleagues asks whether SRI treatment affects the levels of neuroactive steroids that act at GABA-A receptors.
Symptom-onset dosing with a serotonin reuptake inhibitor for PMDD may have a greater impact on anger/irritability and relationship functioning than other symptoms.
In this population seeking treatment for PMDD, suicidal ideation is very common, affecting about 40% of the women.
In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.
About 60% of women with mood disorders experience premenstrual exacerbation or PME of their mood during the premenstrual phase of their cycle.
Some, but not all, studies suggest that PMDD is a risk factor for postpartum depression.
Neuroactive steroids, derivatives of allopregnanolone, may be effective for the treatment of premenstrual dysphoric disorder.
In a recent meta-analysis, Yan and colleagues looked at the prevalence of suicidal ideation among women diagnosed with PMDD.